Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Imugene ( (AU:IMU) ) has shared an announcement.
Imugene Limited has disclosed that U.S.-based Precision BioSciences, Inc. has ceased to be a substantial shareholder in the company following a series of on-market share sales and dilution from a placement. Precision BioSciences reduced its holding through multiple disposals of ordinary shares between January and April 2026, and its interest was further diluted by a 19,298,135-share placement, resulting in the loss of substantial holder status.
The change in Precision BioSciences’ position adjusts Imugene’s shareholder base and may signal a shift in strategic or financial alignment between the two companies. While the announcement does not detail any operational changes, the exit of a substantial holder can influence market perception of Imugene’s capital structure, ownership dynamics, and potentially its future funding or partnership landscape.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.25 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is a biotechnology company focused on developing immuno-oncology therapies, leveraging immune system modulation to target cancer. The company operates in the biopharmaceutical sector, with a market focus on novel cancer treatments that can be combined with existing standards of care to improve patient outcomes.
YTD Price Performance: -71.23%
Average Trading Volume: 1,540,575
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$43.66M
See more data about IMU stock on TipRanks’ Stock Analysis page.